CollPlant Biotechnologies
CLGN
1 hedge funds and large institutions have $1K invested in CollPlant Biotechnologies in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
0.14% less ownership
Funds ownership: 0.14% → 0% (-0.14%)
50% less funds holding
Funds holding: 2 → 1 (-1)
95% less capital invested
Capital invested by funds: $21K → $1K (-$20K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HIIFS
1
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
| $1K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| – | -$21K | -5,304 | Closed |
|
CLGN Hedge Fund Activity: Q4 2019 in Review
1 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q4 2019, worth a combined $1K — down 95% from $21K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CLGN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $21K sold.
- 1 institutional investor held CollPlant Biotechnologies (CLGN) as of Q4 2019, down from 2 in Q3 2019.
- Funds reported $1K of CollPlant Biotechnologies stock for Q4 2019, down 95% quarter-over-quarter.
- 0 funds opened new CollPlant Biotechnologies positions in Q4 2019 and 1 closed out, a net change of -1 holder.
- The largest CollPlant Biotechnologies seller in Q4 2019 was UBS Group, an estimated $21K sold.
Based on aggregated 13F filings for Q4 2019.